Related Experiment Videos
Role of E2F-1 in chemosensitivity
D Banerjee1, B Schnieders, J Z Fu
1Molecular Pharmacology and Experimental Therapeutics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
Cancer Research
|October 10, 1998
Summary
Overexpressing E2F-1 in fibrosarcoma cells accelerated growth and altered chemosensitivity. E2F-1 increased resistance to 5-fluorouracil but enhanced sensitivity to etoposide and doxorubicin.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- The E2F family of transcription factors, with DP proteins, regulates genes essential for DNA synthesis.
- Key cancer drug targets like thymidylate synthase (TS) and dihydrofolate reductase are among these genes.
- Understanding E2F-1's role is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the impact of human E2F-1 cDNA overexpression on chemosensitivity.
- To analyze the effects on cell proliferation and drug response in HT-1080 fibrosarcoma cells.
Main Methods:
- Overexpression of human E2F-1 cDNA in HT-1080 fibrosarcoma cells.
- Assessment of cell doubling time in vitro and in vivo.
- Evaluation of chemosensitivity to various chemotherapeutic agents.
Main Results:
- E2F-1 overexpression led to a reduced doubling time for HT-1080 cells.
- Up-regulation of thymidylate synthase (TS) was observed in E2F-1 transfected cells.
- Cells overexpressing E2F-1 showed increased resistance to 5-fluorouracil but enhanced sensitivity to etoposide, doxorubicin, and SN38, while remaining unaffected by Taxol.
Conclusions:
- E2F-1 overexpression influences cell proliferation and alters chemosensitivity profiles.
- The findings suggest a complex role for E2F-1 in mediating responses to different chemotherapeutic drugs.
- Targeting E2F-1 pathways may offer novel strategies for cancer treatment, depending on the drug regimen.